Sign inJoin waitlistJoin the waitlist

Krista Pfaendler

Medical Director of Quality and Performance Improvement · West Virginia University School of Medicine

Credentials: · · · · · · · · ·

History

Quality and Performance Improvement · West Virginia University School of Medicine
Present
West Virginia University School of Medicine
Present

Gynecologic Oncology
University of California
2015–2018
Obstetrics and Gynecology
University of Cincinnati Medical Center Inc.
2009–2013
University of California, Irvine
University of Pittsburgh School of Medicine
2005–2009
Carnegie Mellon University
2001–2005

Research

Changing paradigms in the systemic treatment of advanced cervical cancer
Review · American Journal of Obstetrics and Gynecology · 2016 · First of 2 authors · 175 citations
Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in…
PLoS ONE · 2015 · 128 citations
Cervical cancer survivorship: long-term quality of life and social support
Review · Clinical Therapeutics · 2015 · First of 4 authors · 119 citations

GP
Groesbeck Parham
16 papers
Jeffrey Stringer
12 papers
Michael Hicks
11 papers
Carla Chibwesha
9 papers · 2 as a resident
Sten Vermund
9 papers
Benjamin Chi
2 papers
James Williams
2 papers
Krishnansu Tewari
2 papers
Kristine Penner
2 papers · 1 as a fellow
Leeya Pinder
2 papers
MH
Maya Hicks
2 papers · 2 as a resident
Robert Bristow
2 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
Site PI · Recruiting
National Cancer Institute (NCI)
2025–2027
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034